Publikationen

2024
Profiling of ERBB receptors and downstream pathways reveals selectivity and hidden properties of ERBB4 antagonists

Popović L, Wintgens J P, Wu Y, Brankatschk B, Menninger S, Degenhart C, Jensen N, Wichert S P, Klebl B, Rossner M J and Wehr M C. iScience. 2024; doi: 10.1016/j.isci.2024.108839

Pyrrolopyrimidine based CSF1R inhibitors: Attempted departure from Flatland

Bjornstad F, Havik S, Aarhus T I, Mahdi I, Unger A, Habenberger P, Degenhart C, Eickhoff J, Klebl B M, Sundby E and Hoff B H. Eur J Med Chem. 2024; 265 116053. doi: 10.1016/j.ejmech.2023.116053

Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA

Teuber A, Schulz T, Fletcher B S, Gontla R, Muhlenberg T, Zischinsky M L, Niggenaber J, Weisner J, Kleinbolting S B, Lategahn J, Sievers S, Muller M P, Bauer S and Rauh D. Nat Commun. 2024; 15 (1): 63. doi: 10.1038/s41467-023-44376-8

2016
Transient P2X7 Receptor Antagonism Produces Lasting Reductions in Spontaneous Seizures and Gliosis in Experimental Temporal Lobe Epilepsy

Jimenez-Pacheco A, Diaz-Hernandez M, Arribas-Blazquez M, Sanz-Rodriguez A, Olivos-Ore L A, Artalejo A R, Alves M, Letavic M, Miras-Portugal M T, Conroy R M, Delanty N, Farrell M A, O'Brien D F, Bhattacharya A, Engel T, Henshall D C. J Neurosci. 2016; 36 (22): 5920-5932. doi: 10.1523/JNEUROSCI.4009-15.2016

Design and synthesis of DNA-encoded libraries based on a benzodiazepine and a pyrazolopyrimidine scaffold

Škopić M K, Bugain O, Jung K, Onstein S, Brandherm S, Kalliokoski T, Brunschweiger A. MedChemComm. 2016; 7 (10): 1957-1965. doi: 10.1039/c6md00243a

Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeutics

Chakedis J, French R, Babicky M, Jaquish D, Mose E, Cheng P, Holman P, Howard H, Miyamoto J, Porras P, Walterscheid Z, Schultz-Fademrecht C, Esdar C, Schadt O, Eickhoff J, Lowy A M. Oncotarget. 2016; 7 (29): 45959-45975. doi: 10.18632/oncotarget.10009

Critical Evaluation of P2X7 Receptor Antagonists in Selected Seizure Models

Fischer W, Franke H, Krugel U, Muller H, Dinkel K, Lord B, Letavic M A, Henshall D C, Engel T. PLoS One. 2016; 11 (6): e0156468. doi: 10.1371/journal.pone.0156468

Identification of pyrazolopyridazinones as PDEδ inhibitors

Papke B, Murarka S, Vogel H A, Martin-Gago P, Kovacevic M, Truxius D C, Fansa E K, Ismail S, Zimmermann G, Heinelt K, Schultz-Fademrecht C, Al Saabi A, Baumann M, Nussbaumer P, Wittinghofer A, Waldmann H, Bastiaens P I. Nat Commun. 2016; 7 11360. doi: 10.1038/ncomms11360

The Evolving Role of the Medicinal Chemist

Lawton G, Nussbaumer P. Prog Med Chem. 2016; 55 193-226. doi: 10.1016/bs.pmch.2015.11.001